NKG2D ligands in tumor immunity: Two sides of a coin

Jinyu Zhang; Fahmin Basher; Jennifer D. Wu

doi:10.3389/fimmu.2015.00097

NKG2D ligands in tumor immunity: Two sides of a coin

Jinyu Zhang, Fahmin Basher, Jennifer D. Wu^*

^*Corresponding author for this work

Urology

Research output: Contribution to journal › Article › peer-review

132 Scopus citations

Abstract

The activating/co-stimulatory receptor NKG2D (natural-killer group 2, member D) is expressed on the surface of all human NK, NKT, CD8⁺ T, and subsets of γδ⁺ T cells. The significance of NKG2D function in tumor immunity has been well demonstrated in experimental animal models. However, the role of human NKG2D ligands in regulating tumor immunity and cancer prognosis had been controversial in the literature. In this review, we summarize the latest advancement, discuss the controversies, and present evidence that membrane-bound and soluble NKG2D ligands oppositely regulate tumor immunity. We also discuss new perspectives of targeting NKG2D ligands for cancer immunotherapy.

Original language	English (US)
Article number	00097
Journal	Frontiers in immunology
Volume	6
Issue number	MAR
DOIs	https://doi.org/10.3389/fimmu.2015.00097
State	Published - 2015

Keywords

Cancer
NK cells
NKG2D ligands
T cells
Tumor immunity

ASJC Scopus subject areas

Immunology and Allergy
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fimmu.2015.00097

Cite this

@article{0c96b7da806f4410a15d716423126948,

title = "NKG2D ligands in tumor immunity: Two sides of a coin",

abstract = "The activating/co-stimulatory receptor NKG2D (natural-killer group 2, member D) is expressed on the surface of all human NK, NKT, CD8+ T, and subsets of γδ+ T cells. The significance of NKG2D function in tumor immunity has been well demonstrated in experimental animal models. However, the role of human NKG2D ligands in regulating tumor immunity and cancer prognosis had been controversial in the literature. In this review, we summarize the latest advancement, discuss the controversies, and present evidence that membrane-bound and soluble NKG2D ligands oppositely regulate tumor immunity. We also discuss new perspectives of targeting NKG2D ligands for cancer immunotherapy.",

keywords = "Cancer, NK cells, NKG2D ligands, T cells, Tumor immunity",

author = "Jinyu Zhang and Fahmin Basher and Wu, {Jennifer D.}",

note = "Publisher Copyright: {\textcopyright} 2015 Zhang, Basher and Wu.",

year = "2015",

doi = "10.3389/fimmu.2015.00097",

language = "English (US)",

volume = "6",

journal = "Frontiers in immunology",

issn = "1664-3224",

publisher = "Frontiers Media SA",

number = "MAR",

}

TY - JOUR

T1 - NKG2D ligands in tumor immunity

T2 - Two sides of a coin

AU - Zhang, Jinyu

AU - Basher, Fahmin

AU - Wu, Jennifer D.

PY - 2015

Y1 - 2015

N2 - The activating/co-stimulatory receptor NKG2D (natural-killer group 2, member D) is expressed on the surface of all human NK, NKT, CD8+ T, and subsets of γδ+ T cells. The significance of NKG2D function in tumor immunity has been well demonstrated in experimental animal models. However, the role of human NKG2D ligands in regulating tumor immunity and cancer prognosis had been controversial in the literature. In this review, we summarize the latest advancement, discuss the controversies, and present evidence that membrane-bound and soluble NKG2D ligands oppositely regulate tumor immunity. We also discuss new perspectives of targeting NKG2D ligands for cancer immunotherapy.

AB - The activating/co-stimulatory receptor NKG2D (natural-killer group 2, member D) is expressed on the surface of all human NK, NKT, CD8+ T, and subsets of γδ+ T cells. The significance of NKG2D function in tumor immunity has been well demonstrated in experimental animal models. However, the role of human NKG2D ligands in regulating tumor immunity and cancer prognosis had been controversial in the literature. In this review, we summarize the latest advancement, discuss the controversies, and present evidence that membrane-bound and soluble NKG2D ligands oppositely regulate tumor immunity. We also discuss new perspectives of targeting NKG2D ligands for cancer immunotherapy.

KW - Cancer

KW - NK cells

KW - NKG2D ligands

KW - T cells

KW - Tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=84926646482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926646482&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2015.00097

DO - 10.3389/fimmu.2015.00097

M3 - Article

C2 - 25788898

AN - SCOPUS:84926646482

SN - 1664-3224

VL - 6

JO - Frontiers in immunology

JF - Frontiers in immunology

IS - MAR

M1 - 00097

ER -

NKG2D ligands in tumor immunity: Two sides of a coin

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this